Skip to main content
Equibles

Point72 Asset Management, L.P.

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1603466 STAMFORD, CT
Back to NTLA Full portfolio

Position in NTLA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$6,741,993
+$3,280,452 QoQ
Shares Held
398,463
+47.6% QoQ
Ownership
0.284%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#48
of 330 holders
Holding Since
Jun 2020
8 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in NTLA Over Time

Shares Held

Position Value (USD)

Derivatives in NTLA

reported options exposure · as of Jun 30, 2026
CallValue
$2,431,404
CallShares
143,700
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Point72 Asset Management, L.P. holds $2,243,273,342 across 172 Biotechnology names. NTLA ranks #69 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ROIV
Roivant Sciences Ltd.
 4,473,478 $158,316,386
2 CYTK
Cytokinetics Inc
 1,587,712 $135,257,185
3 BBIO
BridgeBio Pharma, Inc.
 1,525,782 $113,640,243
4 AXSM
Axsome Therapeutics, Inc.
 416,516 $101,950,621
5 LEGN
Legend Biotech Corp
 3,076,124 $88,838,461
6 MDGL
Madrigal Pharmaceuticals, Inc.
 137,029 $73,577,721
7 CELC
Celcuity Inc.
 650,916 $68,098,831
8 ACAD
Acadia Pharmaceuticals Inc
 2,433,168 $61,559,150

All Filings in NTLA

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,431,404 143,700
2026-06-30 $6,741,993 398,463
2026-03-31 $346,140 27,000
2026-03-31 $3,461,541 270,011
2025-12-31 $216,659 24,100
2025-09-30 $3,009,487 174,261
2021-03-31 $14,478,002 180,400
2020-12-31 $7,915,200 145,500
2020-09-30 $12,984,005 653,119
2020-06-30 $18,306,465 870,907